Qli5 Therapeutics

Dortmund, Germany

Qli5 Therapeutics develops a new class of proteasome inhibitors.

$7.2M raised

Jan 2026

Venture - Series Unknown

Medical Therapeutics

Top Investors

Atinum Partners SV Investment Corp Qurient Therapeutics KHAN Technology Transfer Fund DAOL Investment

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Qli5 Therapeutics

How much funding has Qli5 Therapeutics raised?

Qli5 Therapeutics has raised $7.2M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in January 2026.

Who are Qli5 Therapeutics's investors?

Qli5 Therapeutics's investors include Atinum Partners, SV Investment Corp, Qurient Therapeutics, KHAN Technology Transfer Fund, DAOL Investment.

Where is Qli5 Therapeutics headquartered?

Qli5 Therapeutics is headquartered in Dortmund, Germany.

What does Qli5 Therapeutics do?

Qli5 Therapeutics develops a new class of proteasome inhibitors.

What stage is Qli5 Therapeutics at?

Qli5 Therapeutics is at the Venture - Series Unknown stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 15, 2026.

MLA

"Qli5 Therapeutics — Funding & Investors." VCBacked, January 15, 2026, https://www.vcbacked.co/company/qli5-therapeutics. Accessed July 2, 2026.

APA

VCBacked. (2026). Qli5 Therapeutics — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/qli5-therapeutics

Wikipedia (cite web)

{{cite web |title=Qli5 Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/qli5-therapeutics |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 15, 2026.